Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT<sub>1A</sub> Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study.

Neurol Clin Pract · 2023 · PMC10238151 · PMID 37273942

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Although not powered to demonstrate statistically significant treatment differences, a nonsignificant trend of greater improvement was observed for ulotaront treatment compared with placebo for most outcomes.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.